Completed PHASE2 INTERVENTIONAL 3-arm NCT01238107

A Clinical Study With MT-102 in Subjects With Cancer Cachexia

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects With Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer

Sponsor: Akamis Bio

Conditions Cancer Cachexia

Interventions MT-102

Updated 7 times since 2017 Last updated: Sep 9, 2014 Started: Apr 30, 2011 Primary completion: May 31, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cancer Cachexia, this trial is completed. The trial is conducted by Akamis Bio and has accumulated 7 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Feb 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Akamis Bio
Veeda Oncology

Data source: Akamis Bio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Alor Star, Malaysia , Anand, India , Berlin, Germany , Cheras, Malaysia , Goraj, India , Jalan Baharu, Malaysia , Kilpauk, India , Kuantan, Malaysia , Kubang Kerian, Malaysia and 7 more locations